Product Description
VO-659 is VICO’s investigational antisense oligonucleotide (AON) therapy for the treatment of spinocerebellar ataxia (SCA). (Sourced from: https://www.ataxia.org/pipeline/)
Mechanisms of Action: HTT Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: Orphan Drug - Cerebellar Ataxia|AtaxiaOrphan Drug - Huntington Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: VICO Therapeutics B.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, France, Germany, Netherlands
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Cerebellar Ataxia|Huntington Disease|Machado-Joseph Disease|Spinocerebellar Ataxias Type 1|Spinocerebellar Degenerations
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VO659-CT01 | P2 |
Recruiting |
Spinocerebellar Ataxias Type 1|Spinocerebellar Degenerations|Huntington Disease|Machado-Joseph Disease |
2025-09-01 |
|
| Phase 1/2a open-label trial of VO659 in participants with SCA1, SCA3 and HD | P2 |
Active, not recruiting |
Huntington Disease|Cerebellar Ataxia |
2025-08-02 |
|
| VO659-CT01 | P2 |
Unknown Status |
Huntington Disease|Cerebellar Ataxia |
2025-06-15 |